Cart
sales@molnova.com
LY2608204
CAS No. 1234703-40-2
LY2608204( LY-2608204 | LY 2608204 | LY2608204 )
Catalog No. M17209 CAS No. 1234703-40-2
LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 138 | In Stock |
|
| 50MG | 178 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY2608204
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
-
DescriptionLY-2608204 is an activator of glucokinase (GK) with an EC50 value of 42 nM. LY2608204 decreases plasma glucose in a dose-dependent manner at both fasted and postprandial glucose levels. In 2010, LY-2608204 was entered clinical trials in Patients With Type 2 Diabetes.
-
In Vitro——
-
In Vivo——
-
SynonymsLY-2608204 | LY 2608204 | LY2608204
-
PathwayNeuroscience
-
TargetGluR
-
Recptorglucokinase
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number1234703-40-2
-
Formula Weight559.81
-
Molecular FormulaC28H37N3O3S3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL. 178.63 mM
-
SMILESC1CCC(CC1)[C@@H]1C[C@]1(C(=O)Nc1ncc(s1)SCCN1CCCC1)c1ccc(cc1)S(=O)(=O)C1CC1
-
Chemical Name(1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
KM02894
KM02894 is a glutamate release inhibitor. Cancer cells release high levels of glutamate that can disrupt normal bone turnover, which can lead to cancer-induced bone pain.KM02894 may be used in the study of tumor-related diseases.
-
CPPHA
CPPHA, a positive allosteric modulator of glutamate receptors mGluR5 and mGluR1, is commonly used in development for central nervous system diseases.
-
MNI 137
MNI 137 is a negative allosteric modulator of mGlu2. MNI 137 inhibits glutamate-induced calcium mobilization with IC50s of 8.3 and 12.6 nM for human and rat.
